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With the change in patient population toward older and sickerpatients undergoing cardiac surgery, neurologic injury hasemerged as perhaps the most important perioperative com-plication, and its frequency increases exponentially withincreasing age.1 Particular attention has been paid to the roleof cardiopulmonary bypass per se2 and thromboemboliza-
tion from the ascending aorta.3 However, neurologic injury is not limited to only
stroke and coma1; increasingly there is a focus on the more subtle neurocognitive
dysfunction and its consequences on quality of life.4,5
The majority of cases of gross neurologic injury do not represent a diagnostic
problem, as at the time of diagnosis the injury is usually manifest and irreversible.
Neurocognitive dysfunction, however, is less accessible for quantification, which
requires time-consuming neuropsychologic testing. With only a few exceptions,
such testing has been unavailable for the cardiac surgeon. Prompted by the increas-
ing awareness of neurologic injury, as well as the emergence of minimally invasive
cardiac surgery, there is at present an increasing interest in cognitive testing.
However, such testing will remain a research method and not available in everyday
clinical practice because of the time and manpower it consumes.
A biochemical marker in the blood of the patients—“a troponin of the brain”—
would represent a revolution in the investigation and diagnosis of neurologic injury
in cardiac surgery. A serum marker could potentially identify which aspect(s) of
cardiac surgery are responsible for cognitive dysfunction and evaluate the efficacy
of alternative surgical techniques. Additionally, if marker concentrations during or
directly after surgery could be related to cognitive dysfunction or shown to predict
gross neurologic injury that became clinically evident after some hours (or days),
then potentially neuroprotective interventions might be indicated.
The ideal biochemical marker should have the following properties:
1. Central nervous specificity
2. Rapid and significant release into blood after injury, preferably within minutes
3. Elimination within a few hours
4. Rapidly and readily obtainable assay results
5. Predictability of serious injury from an early sample, eg, at the end of surgery
6. Relationship of marker concentration to the degree of injury, quantifying the
full range from subtle cognitive deficits to gross injury
7. Inexpensive
During the past two decades a variety of substances have been suggested as
possible biochemical markers of brain injury, such as adenylate kinase, creatinine
phosphokinase isoenzyme BB, lactate, myelin basic protein, S100, and neuron-
specific enolase.6 Recently, glial fibrillary acidic protein has been added to this list,7
but its potential role is unknown. Most of these substances have methodologic
problems: for instance, adenylate kinase and lactate have to be sampled directly
from cerebrospinal fluid, and creatinine phosphokinase isoenzyme BB lacks brain
specificity. The value of neuron-specific enolase was also recently shown to be
doubtful because of its association with hemolysis caused by destruction of eryth-
rocytes.8
S100 appeared to fulfill many of the above criteria of an ideal marker.6,9,10
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Serum S100 increases not only after cardiac surgery, but
also in Alzheimer disease, Down syndrome, minor and
major head injury, acute stroke, and after cardiac arrest.9 It
has been suggested to be a prognostic predictor for the
long-term consequences of minor head injuries and the
degree of anoxic brain injury after cardiac arrest.9
Cardiac surgery causes an increase of serum S100 after
less than an hour (ie, before cannulation), a further increase
to maximum blood levels at the end of cardiopulmonary
bypass, and thereafter it rapidly declines,6,9 although occa-
sionally with a late rise. Serum S100 has been correlated
with age, duration of cardiopulmonary bypass, duration of
aortic crossclamping, duration of deep hypothermic circu-
latory arrest, number of cerebral emboli during surgery,
preoperative cerebrovascular complications, and preopera-
tive renal impairment.9 The use of a filter in the arterial line
or heparin-coated surfaces reduces postoperative S100
levels.9 There are anecdotal reports that patients with oper-
ative cerebral injuries have higher concentrations of S100
at the end of surgery.11,12 The relation of S100 to neuro-
cognitive dysfunction is controversial, but most studies do
not find such a correlation.
These findings initiated the tremendous interest in
S100, which was rapidly adopted as the marker of cerebral
injury until recent findings suggested the presence of a
significant noncerebral contribution. Patients operated on
off-pump were shown to lack the large increased concen-
tration seen after bypass, but an assay with increased sen-
sitivity revealed a puzzling increase after only the prebypass
surgical trauma.13 Jo¨nsson and associates14 sampled blood
every hour for the first 10 hours postoperatively, detected
brief elevations of S100 that coincided with the time
points of autotransfusion, and found a 20-fold increase of
S100 in the mediastinal shed blood compared with the
regular blood samples. Anderson and colleagues15,16
showed that if the cardiotomy suction was replaced by a
cell-saving device during surgery with cardiopulmonary
bypass, the serum S100 concentrations during the whole
perioperative period were indistinguishable from those of
patients operated on off-pump. S100 in the cell-saving
reservoir blood was 10-fold greater than the maximum
serum S100 in patients undergoing conventional coronary
artery bypass surgery with cardiopulmonary bypass using a
cardiotomy suction. Pleural drainage blood from patients
having a thoracotomy (no cardiopulmonary bypass) con-
tained equally large S100 concentrations as blood from
mediastinal drains after on-pump cardiac surgery.16 Very
high levels of S100 were detected in blood from the
surgical wounds, from bone marrow aspirate, in mediastinal
fat, and in skeletal muscle—concentrations that were up to
1000 times higher than the preoperative blood concentra-
tions.16 Brain specificity was not improved by separate
analysis of the two dimer subgroups that comprise S100 as
it is commercially assayed.16 Both dimers appear in serum
after surgery and both arise from extracerebral sources,
especially traumatized fat and muscle tissue.
Hopes to use serum S100 to screen patients who have
had head trauma are clouded by the finding that even trauma
patients without head injury have increased concentrations
of serum S100, particularly after bone fractures, but even
after limited soft tissue trauma and burns. These noncerebral
contributions limit the usefulness of serum S100 in neu-
rosurgery.17 Serum S100 increases seen after accidental or
only surgical trauma (such as after off-pump surgery or
on-pump surgery without a cardiotomy reservoir) may be
completely explained, although a cerebral contribution can-
not be excluded, by capillary and lymphatic uptake into the
circulation of the small (11-kd) S100 monomer due to the
high concentration difference between mediastinal blood
and the bloodstream.16
Consequently, extracerebral sources of S100 make the
interpretation of the early S100 blood concentrations dif-
ficult, and no valid conclusions concerning neurologic in-
jury in cardiac surgery can be drawn from the early release.
To a large extent, the correlations previously detected for
S100 levels after cardiopulmonary bypass can be related to
the use of the cardiotomy suction: a longer operation or
more complicated patient population means that more blood
is suctioned from the mediastinum with increased return of
mediastinal blood to the circulation, and thus the higher
serum S100 concentration. All previous data on S100
should be reevaluated in light of this knowledge. The sim-
ilarity of release between on-pump (when a cell saving
system is used) and off-pump surgery suggests that cardio-
pulmonary bypass per se does not release S100.15,16 These
data imply that the early sampling of S100 is useless in
detecting neurologic damage after conventional cardiac sur-
gery using cardiopulmonary bypass because of the high
background noise of S100 release from extracerebral
sources. Late increases in serum S100, after 24 to 48
hours, have been related to perioperative cerebral compli-
cations like stroke, delayed awakening, and confusion.9,12
Unfortunately, this is neither helpful nor really interesting,
because at this stage the brain injury is already manifest and
irreversible and may be quantified in other, probably more
precise ways. The potentially most interesting use of the
serum S100 concentration would have been a detectable
contribution from the brain at or immediately after the
operation.
Two possibilities for the use of early S100 release exist:
1. Can an early high level of serum S100 predict that a
neurologic injury has occurred? This is probably only
possible if the cardiotomy reservoir has not been
used. The contributions from surgical trauma are
smaller, but as cardiopulmonary bypass makes no
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distinguishable addition, any correlation with cogni-
tive dysfunction is below the level of detection.
2. Sampling of cerebrospinal fluid for measurements of
S100 may avoid the above problems, although a
spinal tap may create additional problems. Spinal
fluid drainage presents a unique opportunity to com-
pare cerebrospinal fluid and blood levels of S100.
In this issue of the Journal, Kunihara, Shiiya, and Ya-
suda18 compared values in serum and in cerebrospinal fluid
of patients undergoing surgery for thoracoabdominal aneu-
rysms. The number of patients in each group is small, but
the study shows higher sensitivity and earlier release of
S100 into the cerebrospinal fluid when spinal injury oc-
curred. More such studies are needed to investigate whether
S100 has any place at all as an early marker of neurologic
injury in cardiovascular surgery. At the present time, using
serum S100 concentrations immediately after the end of
bypass as a marker of neurologic injury is not acceptable if
a cardiotomy suction has been used. In addition, any tissue
damage will limit its usefulness, particularly in diagnosing
the subtle changes of greatest interest.
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